Details for Patent: 10,004,717

Which drugs does patent 10,004,717 protect, and when does it expire?

Patent 10,004,717 protects QBREXZA and is included in one NDA.

This patent has twenty-five patent family members in thirteen countries.

Summary for Patent: 10,004,717

Title:	Glycopyrrolate salts
Abstract:	Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed.
Inventor(s):	Statler; John Allan (Redwood City, CA), Shaw; Anthony Adrian (North Vancouver, CA), Imbert; Delphine Caroline (Cupertino, CA), Nelson; Jennifer Leigh (Kokomo, IN), Andres; Patricia (West Lafayette, IN), McQueen; Lisa Lynn (West Lafayette, IN), Boerrigter; Stephan Xander Mattheus (West Lafayette, IN), Selbo; Jon Gordon (West Lafayette, IN), Andres; Mark Christopher (West Lafayette, IN)
Assignee:	DERMIRA, INC. (Menlo Park, CA)
Application Number:	15/438,636
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,004,717
Patent Claim Types: see list of patent claims	Use; Formulation; Compound;

Drugs Protected by US Patent 10,004,717

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Journey	QBREXZA	glycopyrronium tosylate	CLOTH;TOPICAL	210361-001	Jun 28, 2018		RX	Yes	Yes			Y			TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER

International Family Members for US Patent 10,004,717

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014223172
Australia	2016269524
Canada	2902795
China	105026369